p28GANK associates with p300 to attenuate the acetylation of RelA

Molecular Carcinogenesis

Volumn 54, Issue 12, 2015, Pages 1626-1635

  Ren, Y B ^a,b   Luo, T ^a,b   Li, J ^c   Fu, J ^a,b   Wang, Q ^a   Cao, G W ^a   Chen, Y ^a,b   Wang, H Y ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b National Center for Liver Cancer   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; NF B; P28GANK; P65

Indexed keywords

DOXORUBICIN; E1A ASSOCIATED P300 PROTEIN; FAS ANTIGEN; FAS LIGAND; HISTONE DEACETYLASE 3; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; ONCOPROTEIN; PROTEIN BCL XL; PROTEIN P28GANK; PROTEIN P53; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; EP300 PROTEIN, HUMAN; I KAPPA B; NF-KAPPAB INHIBITOR ALPHA; PROTEASOME; PSMD10 PROTEIN, HUMAN; RELA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CARCINOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ACETYLATION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSLATION REGULATION; TUMOR CELL; ACETYLATION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; HEPG2 CELL LINE; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; TRANSGENIC MOUSE;

ACETYLATION; ANIMALS; ANTIGENS, CD95; CARCINOMA, HEPATOCELLULAR; DOXORUBICIN; E1A-ASSOCIATED P300 PROTEIN; FAS LIGAND PROTEIN; HEK293 CELLS; HEP G2 CELLS; HUMANS; I-KAPPA B PROTEINS; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84945449588     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22235     Document Type: Article

References (32)

1. Higashitsuji H, Itoh K, Nagao T, et al. Redued stability of retinoblastoma protein by gankyrin an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med 2000; 6:96-99.
2. Fu XY, Wang HY, Tan L, Liu SQ, Cao HF, Wu MC. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J Gastroenterol 2002; 8:638-643.
3. Baumeister W, Walz J, Zuhl F, Seemuller E. The proteasome: Paradigm of a self-compartmentalizing protease. Cell 1998; 92:367-380.
4. Hori T, Kato S, Saeki M, et al. cDNA cloning and functional analysis of p28 (Nas6p) and p40.5 (Nas7p), two novel regulatory subunits of the 26S proteasome. Gene 1998; 216:112-113.
5. Higashitsuji H, Itoh K, Sakurai T, et al. The oncoprotein gankyrin binds to MDM2/HDM2 enhanceing ubiquitylation and degradation of p53. Cancer Cell 2005; 8:75-87.
6. Baldwin AS Jr. The NF-κB and IκBs proteins: new discoveries and insights. Annu Rev Immunol 1996; 14:649-683.
7. Karin M, Lin A. NF-kB at the crossroad of life and death. Nat Immunol 2002; 3:221-227.
8. Hayden MatthewS, Sankar Ghosh. Signaling to NF-κB. Genes Dev 2004; 18:2195-2224.
9. Chen LF, Greene WC. Assessing acetylation of NF-κB. Methods 2005; 36:368-375.
10. Zhong H, SuYang H, Erdjument-Bromage H, Tempst P, Ghosh S. The transcriptional activity of NF-κB is regulated by the IκB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 1997; 89:413-424.
11. Wang D, Westerheide SD, Hanson JL, Baldwin AS Jr. Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000; 275:32592-32597.
12. Luedde T, Beraza N, Kotsikoris V, et al. Deletion of NEMO/IKK gamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11:119-132.
13. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-κB determines its association with CBP/p300 or HDAC-1. Mol Cell 2002; 9:625-636.
14. Campbell KJ, Perkins ND. Post-translational modification of RelA(p65) NF-κB. Biochem Soc Trans 2004; 32:1087-1089.
15. Chen Y, Li HH, Fu J, et al. Oncoprotein p28GANK binds to RelA and retains NF-κB in the cytoplasm through nuclear export. Cell Res 2007; 12:1020-1029.
16. Higashitsuji H, Liu Y, Masuda T, et al. The oncoprotein gankyrin interacts with RelA and suppresses NF-κB activity. Biochem Biophys Res Commun 2007; 363:879-884.
17. Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 2012; 148:72-83.
18. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001; 293:1653-1657.
19. Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol 2002; 2:725-734.
20. Alao JP, Stavropoulou AV, Lam EW, Coombes RC, Vigushin DM. Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer 2006; 5:8.
21. Fu J, Chen Y, Cao J, et al. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways. Hepatology 2011; 53:181-192.
22. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptionalcoactivators p300 and CBP are histone acetyltransferases. Cell 1996; 87:953-959.
23. Kiernan R, Bres V, Ng RWM, et al. Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003; 278:2758-2766.
24. Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 2000; 64:435-459.
25. Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-κB in p53-mediated programmed cell death. Nature 2000; 404:892-897.
26. Higashitsuji H, Itoh K, Sakurai T, et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 2005; 8:75-87.
27. Liu Y, Higashitsuji H, Higashitsuji H, et al. Overexpression of gankyrin in mouse hepatocytes induces hemangioma by suppressing factor inhibiting hypoxia-inducible factor-1 (FIH-1) and activating hypoxia-inducible factor-1. Biochem Biophys Res Commun 2013; 432:22-27.
28. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121:977-990.
29. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001; 107:241-246.
30. Kaltschmidt B, Kaltschmidt C, Hofmann TG, Hehner SP, Droge W, Schmitz ML. The pro- or anti-apoptotic function of NF-κB is determined by the nature of the apoptotic stimulus. Eur J Biochem 2000; 267:3828-3835.
31. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18:6853-6866.
32. Li H, Fu X, Chen Y, et al. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology 2005; 128:2029-2041.